High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. - Wikidata - wikimedia - TriplyDB

High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a.

High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a.

http://www.wikidata.org/entity/Q27824871

about

Essential thrombocythemia The Role of Reactive Oxygen Species in Myelofibrosis and Related Neoplasms Myeloproliferative and thrombotic burden and treatment outcome of thrombocythemia and polycythemia patients CIViC database The treatment of polycythaemia vera: an update in the JAK2 era Emerging drugs for myelofibrosis.2016 WHO Clinical Molecular and Pathological Criteria for Classification and Staging of Myeloproliferative Neoplasms (MPN) Caused by MPN Driver Mutations in the JAK2, MPL and CALR Genes in the Context of New 2016 WHO Classification: Prognostic and T The role of HLA-G in immunity and hematopoiesis.Treatment with the Bcl-xL inhibitor ABT-737 in combination with interferon α specifically targets JAK2V617F-positive polycythemia vera hematopoietic progenitor cells Interferon-alpha targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway.The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon α 2a target JAK2V617F-positive progenitor and stem cells.Decrease in JAK2 V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera.Comparative long-term effects of interferon α and hydroxyurea on human hematopoietic progenitor cells.Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment.Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera.Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b.Combination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-α 2a specifically targets JAK2V617F-positive polycythemia vera cells Experience with pegylated interferon α-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients Update on JAK2 Inhibitors in Myeloproliferative Neoplasm Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal.Significant increase in the apparent incidence of essential thrombocythemia related to new WHO diagnostic criteria: a population-based study.Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM090 Anagrelide: 20 years later.Mutational analysis in BCR-ABL-negative classic myeloproliferative neoplasms: impact on prognosis and therapeutic choices.A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms.Thrombosis in myeloproliferative neoplasms with JAK2V617F mutation.Advances in molecular diagnostics of myeloproliferative disorders.The Hepatocyte Growth Factor (HGF)/Met Axis: A Neglected Target in the Treatment of Chronic Myeloproliferative Neoplasms?Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial.Melting point assay for the JAK2 V617F mutation, comparison with amplification refractory mutation system (ARMS) in diagnostic samples, and implications for daily routine.Concordance of assays designed for the quantification of JAK2V617F: a multicenter study.HLA-G turns off erythropoietin receptor signaling through JAK2 and JAK2 V617F dephosphorylation: clinical relevance in polycythemia vera.Real-Time PCR and Droplet Digital PCR: two techniques for detection of the JAK2(V617F) mutation in Philadelphia-negative chronic myeloproliferative neoplasms.Sensitive and accurate quantification of JAK2 V617F mutation in chronic myeloproliferative neoplasms by droplet digital PCR.Minimal residual disease after long-term interferon-alpha2 treatment: a report on hematological, molecular and histomorphological response patterns in 10 patients with essential thrombocythemia and polycythemia vera.Bedside to bench: interfering with leukemic stem cells.Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells.

P2860

Q21202968-D59E093A-712B-4F70-BDBE-5FC572FC9B63 Q26779929-3F3D0F40-3900-48CB-A9B3-06FCDF4E7898 Q26799388-A6DD9B31-A20D-4FE9-9649-C58DC4794C0E Q27612411-315C783A-8D9B-4C9B-B749-CB068F8DF815 Q28212560-FD111CBA-0A5A-446E-B716-402748634C2A Q33404574-C4490D3E-3880-4E25-8A58-8D31064B9761 Q33572605-F8E78BE8-9E8F-4D7C-97A4-B946BDDB6F49 Q34024865-1670D2C0-778A-47C5-9212-51E9885679F0 Q34360366-77C261AE-039F-4802-9223-3BC6B05EE8B3 Q34949540-A2E784B2-D658-428F-838C-418EDC7F8AEF Q35743852-57664643-B7FA-4838-886C-69B772E559D1 Q35944657-2A3A214D-879D-4FBF-BE0A-72FDBB3EFE9A Q36119271-A5035635-01D2-4D27-B3AB-4C4170E31042 Q36169641-D8666F28-7BB6-45C0-8521-8C03533C56E8 Q36169783-A04CE0D1-1F61-4B6E-91ED-C5E499333F82 Q36311347-74339E98-A490-4450-8C52-8C0786A9B8FA Q36318162-3A034CC0-4C90-43D3-8C49-BE8B4EA87BCC Q36366962-B846568C-FADD-4F30-947B-78C139ED380B Q36612569-AE04EC14-B16D-404C-8B4D-DD6EB0E75718 Q36814639-B767E383-E78E-47AA-9B46-EF8C78915A17 Q36938773-F0FFC9D9-7665-4F3D-B854-46DEC7F5A856 Q37083947-2105EFB7-BBFA-4D5C-8BCB-D042609B616B Q37170349-8B69D454-42D9-4149-A401-C4F83A5FB4AD Q37207792-C64CC4CA-AB18-4183-82A1-6F74258AE8C7 Q37250169-381A41F4-BEEA-4A2C-A9CC-73FC608FEDB6 Q37357291-B98F7838-C62C-41A6-8B97-ED3F59BBC259 Q37705374-7A78023D-31BB-494F-90BA-28B665753575 Q37955231-ED1200CC-C880-452F-B106-09DAC7F15870 Q38028927-33629E30-4F5E-40F3-A4BD-E16016B53698 Q38089228-60BD9D80-6A8B-4807-8586-65FD08EAF63E Q38239580-4ED35F72-77B4-4B06-A8CA-DB7A23E47622 Q38909050-189C2411-FAE5-4112-8503-1D334F134F4E Q39691088-16B7E927-D808-4554-9317-5F7D3192DB04 Q39918869-4FCEF947-F88C-4C98-8D5F-0AB1856B2615 Q40039592-7A7C3199-485B-4721-BCA2-938CBEFFC7D4 Q40297835-003A2762-E8CD-426F-9AB3-AFCD82B113A6 Q40356455-BCE47A4A-4B14-4D7B-8C0A-0B1C9A5B85DF Q40959669-AB7ADEF9-075F-4AE3-B6F6-455964205835 Q41463650-2076AA3F-9F17-4B56-9153-58935C217538 Q41765680-7E9A5B8D-72CB-4023-B92E-55709B00A169

P2860

High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a.

http://www.wikidata.org/entity/Q27824871

description

2006 nî lūn-bûn

@nan

2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

High molecular response rate o ...... pegylated interferon alpha-2a.

@ast

High molecular response rate o ...... pegylated interferon alpha-2a.

@en

High molecular response rate o ...... pegylated interferon alpha-2a.

@nl

type

label

High molecular response rate o ...... pegylated interferon alpha-2a.

@ast

High molecular response rate o ...... pegylated interferon alpha-2a.

@en

High molecular response rate o ...... pegylated interferon alpha-2a.

@nl

prefLabel

High molecular response rate o ...... pegylated interferon alpha-2a.

@ast

High molecular response rate o ...... pegylated interferon alpha-2a.

@en

High molecular response rate o ...... pegylated interferon alpha-2a.

@nl

P1433

Q27824871-EAB8B913-5136-4815-9281-F4C02D4A0B6A

P1476

Q27824871-554C4931-751D-4A17-895C-996C967A15CB

P2093

Q27824871-0500A1BF-1CD6-4B5D-A953-3F9166164380

Q27824871-3383217D-1903-4720-AC1A-DED344348A47

Q27824871-39FAB341-3520-4143-B1D7-5C9099176F15

Q27824871-3ACBBADD-B9D1-4279-9433-FBE32FD34F31

Q27824871-456F2CA4-740E-4AA6-B9E0-2D54948DCDD2

Q27824871-4B43FB68-0841-4F74-9F31-EB5F47095AAA

Q27824871-4B6E66E9-496A-4B58-A20B-DE4C02DD85B1

Q27824871-67FFD7C3-0A34-4122-8FB1-9C33E6ACECEC

Q27824871-98756D5D-8C1E-4F24-99DD-9582DEFA2C06

Q27824871-9E5EFDD8-169F-42D6-8AF2-92804F79C411

P304

Q27824871-87EE2154-9A16-4CAD-ABD7-5A3EE093BAC8

P31

Q27824871-F36113A4-8FCA-4F88-B2F6-E80EBC12F8CB

P3181

Q27824871-71485592-9EFF-4510-9EE9-1C8174649AEA

P356

Q27824871-29D1B03F-868D-4687-88FE-BA126F92421E

P407

Q27824871-E1A6E484-D131-403C-AF11-4432F36342EF

P433

Q27824871-008210C3-86D5-4B34-9C30-C4ECDD241EB8

P478

Q27824871-00B4C71F-0FD3-4874-9957-D0DD837335D0

P50

Q27824871-04CC50A0-E590-4444-B12B-4ABDD6EF1322

Q27824871-371F4DDF-1DBB-40A0-AC27-C8111CC6E8A2

Q27824871-8127A41E-99CA-472B-8FC5-2C57029D3DB3

Q27824871-841E3887-197C-449F-8A3F-EDC56E3EEEA0

Q27824871-BD25FC41-50B0-47B2-BE2A-2CDB107EA5D7

Q27824871-D251C724-AB69-4A50-84A2-5E794330AED3

Q27824871-DE46E8B3-9E8E-4569-9D5D-4F33F1DF1855

P577

Q27824871-FFFC896E-9169-4B58-BCBA-7F43B84673C2

P5875

Q27824871-E7093A43-7138-449B-A005-9FE33CCE9A3C

P698

Q27824871-8D99A880-E017-46BF-A74C-1F8A14DE7701

P3181

P356

BLOOD-2006-03-009860

P1433

P1476

High molecular response rate o ...... pegylated interferon alpha-2a.

@en

P2093

Gerald Massonnet

http://www.w3.org/2001/XMLSchema#string

Jean-Didier Rain

http://www.w3.org/2001/XMLSchema#string

Jean-François Bernard

http://www.w3.org/2001/XMLSchema#string

Jean-Luc Dutel

http://www.w3.org/2001/XMLSchema#string

Kamel Ghomari

http://www.w3.org/2001/XMLSchema#string

Lina Abdelkader-Aljassem

http://www.w3.org/2001/XMLSchema#string

Marie-Jose Grange

http://www.w3.org/2001/XMLSchema#string

Marie-Laurence Menot

http://www.w3.org/2001/XMLSchema#string

Nathalie Cambier

http://www.w3.org/2001/XMLSchema#string

Nathalie Parquet

http://www.w3.org/2001/XMLSchema#string

P304

2037-40

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2884854

http://www.w3.org/2001/XMLSchema#string

P356

10.1182/BLOOD-2006-03-009860

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

108

http://www.w3.org/2001/XMLSchema#string

P50

William Vainchenker

Jean-Jacques Kiladjian

Murielle Roussel

Christine Chomienne

P577

2006-09-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7071684

http://www.w3.org/2001/XMLSchema#string

P698

16709929

http://www.w3.org/2001/XMLSchema#string